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THU0044 IMPAIRED AUTOPHAGY INDUCES DEFECTIVE
FUNCTION OF REGULATORY B CELLS IN ANKYLOSING
SPONDYLITIS
C. Shuizhong, X. zhongyu, Z. guan, S. huiyong, W. yanfeng. Department of
Orthopedics, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China
Background: Ankylosing spondylitis (AS) is an autoimmune disease character-
ised by pathological osteogenesis and chronic inflammation. Large number stud-
ies shown that Regulatory B cells (Bregs) has immunosuppressive function,
which could be involved in many rheumatic disease, such as systemic lupus eryth-
ematosus (SLE), rheumatoid arthritis (RA). But the Bregs in AS are poorly
understood.
Objectives: To investigate the ratio and function of Bregs in AS, and illuminate
the under lying mechanism, which might help to further understand the pathology
of AS.
Methods: (1) Peripheral blood mononuclear cells (PBMCs) were collected from 9
AS patients and 9 healthy controls, then the Bregs were detected by using flow
cytometry with the following antibodies: CD19-PE, CD24-FITC and CD38-APC.2
B cells were purified with a CD19 magnetic bead, the Bregs were sorted by using
the flow cytometry. Bregs were added to the upper chamber with 1.5 ml medium,
while CD4 +T cells were added to the lower chamber with 2.6 ml medium at a ratio
of 1:1 Bregs(1 × 106 cells): CD4 +T cells(1 × 106 cells). CD4 +T cells were incu-
bated with 5 mM CFDA-SE. The CD4 +T cell proliferation was analyse in the fifth
day.3The cytokines of Bregs were detected with a proteome profiler kit, and con-
firmed by using Elias and Western Blot.4 We detected the Bregs autophagy
between AS and HD. And we regulate the autophagy with rapamycin and 3-meth-
yladenine (3-MA), then detected the IL-10 secretion of Bregs and the CD4 +T cell
proliferation among groups.
Results: (1) The ratio of Bregs in AS was higher that in healthy group.2
Bregs from AS shown a impaired function in suppressed the CD4 +T cell
proliferation compared with HD.3 Bregs of AS expressed and secreted less
IL-10 than healthy control, and might explain the impaired function of Bregs
of AS.4 Exogenous IL-10 recovered the immunosuppressive capacity of AS
Bregs, whereas exogenous anti-IL-10 antibody reduced the immunosuppres-
sive capacity of HD Bregs.5 Autophagy impaired in AS Bregs compared with
HD Bregs. Induce autophagy in AS Bregs could increase the IL-10 secretion
and strengthened its immunosuppressive capacity, while 3-MA shown the
opposite results.
Conclusions: Even increasing ratio of Bregs in AS, but they had a impaired func-
tion in suppressed CD4 +T cell proliferation compared with the HD. We further
found that impaired autophagy could induces less IL-10 secretion, which further
affected the immunosuppressive capacity of Bregs of AS.
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Background: T follicular helper (Tfh) cells are essential for the generation of high
affinity neutralising antibodies elicited following vaccination and are involved in
the pathogenesis of rheumatoid arthritis (RA). Interleukin (IL)6 has been shown
to be critical for Tfh differentiation in mice, while its importance in humans has
been less clear, given the lack of adequate in vivo assessment.
Objectives: To investigate the importance of IL-6 for the in vivo differentiation of
human Tfh cells, taking advantage of influenza vaccination in patients under anti-
IL-6R therapy.
Methods: Blood was collected before, 7 and 28 days after vaccination from
established RA patients treated with tocilizumab (TCZ, IL-6R blocker), methotrex-
ate (MTX) ±other DMARDs and age- and sex-matched healthy donors (HD). We
analysed the frequency of Tfh (CD3+CD4+CD25-Foxp3-CXCR5+CD45RO+), T fol-
licular regulatory (Tfr, CD3+CD4+CD25+Foxp3+CXCR5+) and B cell populations
at each time point. We used non-parametric tests, deemed significant at p<0.05.
Results: We included 137 participants (42 TCZ, 42 MTX, 53 HD) with similar age
and gender distribution. Patients from the TCZ group had more active and severe
disease. At baseline, patients treated with TCZ had higher frequency of Tfh and
Tfh-Th2-like cells (CXCR3-CCR6-) and lower frequency of Tfr-Th1-like
(CXCR3+CCR6-) and B cells. Following influenza vaccination, the overall blood
Tfh and Tfr populations remained unchanged in all groups. However, as previ-
ously reported, there were marked changes in specific subsets at day 7 of HD fol-
lowing vaccination. We found a marked expansion of activated CXCR5+ICOS+
Tfh cells at day 7, in HD and MTX-treated patients, but this was impaired in the
TCZ group (figure 1). The increase in activated CXCR5+ICOS+ Tfh cells was
mainly due to a Tfh-Th1-like subpopulation, greatly increased in HD and MTX-
treated patients (figure 1). Of note, CXCR5+ICOS+ Tfh-Th17-like cells also accu-
mulated in HD but not in RA patients. The proliferative capacity of CXCR5+ICOS+
Tfh cells seemed to be partially impaired in patients under IL-6R blockade, that
displayed marked reduction of Ki67+CD38+ proliferative cells within that compart-
ment (figure 1). Anti-IL-6R treatment also impaired expansion of CD19+IgD-
CD27+CD38hi plasmablasts following vaccination, when compared with both MTX
and HD groups (figure 1). Changes in CXCR5+ICOS+ Tfh and plasmablasts were
significantly correlated in all groups.
Abstract THU0045 – Figure 1. Frequency of cell populations within the CD4+ in the blood.
All tests are paired and non-parametric. Healthy N=53, MTX N=42, TCZ N=42.
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Conclusions: Anti-IL-6R treatment limits proliferative ability of activated
CXCR5+ICOS+ Tfh cells, blocking their emergence as well as plasmablast accu-
mulation following influenza vaccination. Our data suggest that IL-6 is crucial for
optimal in vivo generation of activated Tfh cells in humans.
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THU0046 SMALL MOLECULE INHIBITOR OF THE WNT PATHWAY
(SM04755) AS A POTENTIAL TOPICAL TREATMENT
FOR PSORIASIS
V. Deshmukh, M. Pedraza, L. Lamangan, Y. Yazici. Samumed, LLC, San Diego,
USA
Background: Psoriasis (PSO) is an autoimmune disease, causing patches of
thick, inflamed, scaly skin due to excessive proliferation of skin cells1. Wnt signal-
ling plays an important role in PSO, regulating inflammation and keratinocyte pro-
liferation. SM04755, a novel, topical small-molecule Wnt pathway inhibitor was
previously shown to inhibit inflammation and keratinocyte proliferation in vitro and
in an IMQ-induced mouse PSOmodel2.
Objectives: In this study, the effects of SM04755 on inflammation and skin health
were evaluated in two models that closely resemble human PSO pathophysiol-
ogy: reconstitution of ICR scid mice with minor histocompatibility mismatched
naïve CD4+ T lymphocytes3 and an IL-23 intra-dermal injection model4.
Methods: For (A) immune reconstitution model, peripheral blood mononuclear
cells were isolated from F2 (BALB/c x 129/SvJ) mice and analysed by flow cytom-
etry to identify H-2Dd haplotype donor mice. CD4+/CD45RBHi cells from donor
mice spleens were purified and injected intravenously into CB17/ICR-Tac Prkdc/
scid (ICR scid) mice (5 × 105 cells/mouse). Skin appearance and ear thickness
were evaluated weekly. At the first visible PSO-like signs, mice were randomised
and treated with SM04755 (400 mg/cm2) or vehicle. After 14 weeks, body and
spleen weights were measured, and inflammation was evaluated by measuring
cytokines (IL-1b, TNF-a, IL-6) in tissues from skin, ears, spleen and plasma using
ELISA. Epidermal thickness and skin immune cell infiltration were histologically
evaluated. For (B) the IL-23 model, rIL-23 was injected intra-dermally into mouse
ears, every other day for 35 days. Mice were randomised on Day 16 and treated
with SM04755 (400 mg/cm2) or vehicle or Clobetasol daily for 20 days. Ear thick-
ness was measured every 3 days. Skin immune cell infiltration was histologically
evaluated.
Results: (A) Immune reconstitution of ICR scid mice resulted in PSO-like signs,
with skin lesions and increased thickness of the skin and ears. Treatment with top-
ical SM04755 (400 mg/cm2) significantly (p<0.01) decreased skin and ear thick-
nesses and improved skin appearance compared to vehicle. Body weights were
significantly (p<0.05) higher in treated compared to vehicle mice. SM04755 signifi-
cantly reduced histologically measured epidermal thickness (p<0.05) and immune
cell infiltration in the skin compared to vehicle. Further, inflammatory cytokine lev-
els in the skin, ears, spleen and plasma and spleen weight were significantly
(p<0.05) reduced in SM04755 treated animals compared with vehicle. (B) Intra-
dermal IL-23 injection into mouse ears resulted in inflammation and ear thickening
by day 16 compared to sham. Treatment with topical SM04755 (400 mg/cm2) sig-
nificantly (p<0.05) decreased ear thickness, immune cell infiltration, and improved
appearance compared to vehicle.
Conclusions: In two mouse models of (A) minor histocompatibility mismatched T
lymphocyte reconstitution-induced PSO and (B) IL-23 injection-induced PSO,
topically applied SM04755 inhibited key pathophysiological features of PSO at
macro- and microscopic levels, compared to vehicle. SM04755 has potential as a
topical therapy for PSO. Clinical trials are ongoing.
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THU0047 1,25(OH)2D3 AND DEXAMETHASONE ADDITIVELY
SUPPRESS SYNOVIAL FIBROBLAST ACTIVATION BY
CCR6+ TH MEMORY CELLS AND ENHANCE THE
EFFECT OF TNF-ALPHA BLOCKADE
W. Dankers1,2, W. Dankers1,2, N. Davelaar1,2, P.S. Asmawidjaja1,2, A.M. Mus1,2, J.
M. Hazes1, E.M. Colin3, E. Lubberts1,2. 1Rheumatology; 2Immunology, Erasmus
MC, Rotterdam; 3Rheumatology, Hospital Group Twente, Almelo, Netherlands
Background: Despite improvement in treatment of rheumatoid arthritis (RA) over
the past decades, insufficient treatment response and treatment resistance in
many patients demonstrate the need to develop new therapeutic strategies.
Chronic synovial inflammation could be suppressed by targeting activation of RA
synovial fibroblasts (RASF) by for example IL-17A-producing CCR6 +T helper
memory (memTh) cells. Previously, we have shown that dexamethasone (DEX)
combined with the active vitamin D metabolite 1,25(OH)2D3 reduces pathogenic-
ity of memTh cells.
Objectives: To study the additive effect of 1,25(OH)2D3 and DEX on suppressing
the pro-inflammatory loop between RASF and CCR6 +memTh cells and explore
potential therapeutic applications.
Methods: CCR6 +memTh cells from PBMC of healthy donors or treatment-naïve
early RA patients were cultured alone or with RASF from established RA patients
for three days and treated with or without 1,25(OH)2D3, DEX or etanercept. Treat-
ment effects were assessed using ELISA and flow cytometry.
Results: CCR6 +memTh produces less of the pro-inflammatory cytokines IL-
17A, IL-22 and IFNg upon exposure to 1,25(OH)2D3, and to a lesser extent by
DEX. TNFa was only inhibited by the combination of 1,25(OH)2D3 and DEX. In
contrast, in RASF cultures DEX was the strongest inhibitor of IL-6, IL-8 and tissue-
destructive enzymes. As a result, 1,25(OH)2D3 and DEX additively inhibited
inflammatory mediators in CCR6 +memTh RASF co-cultures. Interestingly, low
doses of mainly DEX, but also 1,25(OH)2D3, combined with etanercept better sup-
pressed synovial inflammation in this co-culture model compared to etanercept
alone.
Conclusions: This study suggests that 1,25(OH)2D3 and DEX additively inhibit
synovial inflammation through targeting different pro-inflammatory mechanisms.
Furthermore, low doses of DEX and 1,25(OH)2D3 enhance the effect of TNFa
blockade in inhibiting RASF activation, providing a basis to improve RA treatment.
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THU0048 PRO-INFLAMMATORY IL-17A-PRODUCING CCR6+ T
HELPER MEMORY CELLS CHANGE INTO ANTI-
INFLAMMATORY CELLS WITH REGULATORY
CAPACITY UPON EXPOSURE TO ACTIVE VITAMIN D
W. Dankers1,2, N. Davelaar1,2, J.P. van Hamburg1,2, J. van de Peppel3, E.
M. Colin4, E. Lubberts1,2. 1Rheumatology; 2Immunology; 3Internal Medicine,
Erasmus MC, Rotterdam; 4Rheumatology, Hospital Group Twente, Almelo,
Netherlands
Background: In autoimmune diseases such as rheumatoid arthritis (RA), an
important therapeutic goal is to normalise the imbalance between pro- and anti-
inflammatory cells. In RA, especially pro-inflammatory CCR6 +T helper (Th)
memory cells, characterised by IL-17A production and RORC expression, are ele-
vated and more activated compared to healthy controls. Therefore, modulating
these cells to become anti-inflammatory could contribute to restoring the immuno-
logical balance. Interestingly, the active vitamin D metabolite 1,25(OH)2D3 inhibits
pro-inflammatory cytokine production by CCR6 +Th memory cells.
Objectives: We investigated whether 1,25(OH)2D3 can induce an anti-inflamma-
tory phenotype in these memory CCR6 +Th cells.
Methods: CCR6 +Th memory cells, excluding Tregs, were sorted from treat-
ment-naïve early RA patients or healthy controls and cultured with or without 1,25
(OH)2D3. Effects were analysed using microarray, RT-PCR, ELISA or flow cytom-
etry. Functional properties were assessed via suppression and chemotaxis
assays.
Results: 1,25(OH)2D3 inhibits pro-inflammatory cytokines such as IL-17A, IL-17F
and IL-22 in CCR6 +Th memory cells from both healthy controls and RA patients.
This is accompanied by induction of anti-inflammatory factors, including IL-10 and
CTLA4. Interestingly, these formerly pathogenic cells suppress proliferation of
autologous CD3 +T cells, similar to classical Tregs. Importantly, the modulated
memory cells still migrate towards the site of inflammation, modelled by synovial
fluid, and retain their suppressive capacity in this environment.
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